Oppenheimer initiated coverage of Viatris Inc. with an outperform rating. The firm set a price target of $25.00 per share. This target represents a substantial premium over recent trading levels.
Analysts believe the market currently undervalues the company's generics and established-brands portfolio. The firm identifies an improving base business and ongoing cost-saving measures.
The late-stage pipeline includes two assets with blockbuster potential. Oppenheimer also highlighted strong cash generation. Management continues to execute an aggressive share buyback program.